Vivodyne, a biopharma startup co-founded by Penn Engineering Associate Professor of Bioengineering Dan Huh and Bioengineering PhD candidate Andrei Georgescu, launched earlier this year and successfully raised $5M in seed capital from Kairos Ventures.
Vivodyne is further developing a platform technology that allows thousands of individually lab-grown, living pieces of human organs to be cultivated at the same time. By testing drugs and life-saving biologics directly on these realistic human tissues for safety and effectiveness at an unprecedented scale and resolution, the company believes they can greatly improve the success rates of therapeutics entering clinical trials.
